Kraj: Unia Europejska
Język: angielski
Źródło: EMA (European Medicines Agency)
lacosamide
UCB Pharma SA
N03AX18
lacosamide
Antiepileptics,
Epilepsy
Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
Revision: 46
Authorised
2008-08-29
134 B. PACKAGE LEAFLET 135 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT VIMPAT 50 MG FILM-COATED TABLETS VIMPAT 100 MG FILM-COATED TABLETS VIMPAT 150 MG FILM-COATED TABLETS VIMPAT 200 MG FILM-COATED TABLETS lacosamide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Vimpat is and what it is used for 2. What you need to know before you take Vimpat 3. How to take Vimpat 4. Possible side effects 5. How to store Vimpat 6. Contents of the pack and other information 1. WHAT VIMPAT IS AND WHAT IT IS USED FOR WHAT VIMPAT IS Vimpat contains lacosamide. This belongs to a group of medicines called “antiepileptic medicines”. These medicines are used to treat epilepsy. • You have been given this medicine to lower the number of fits (seizures) you have. WHAT VIMPAT IS USED FOR • Vimpat is used: ▪ on its own and in association with other antiepileptic medicines in adults, adolescents and children aged 2 years and older to treat a certain type of epilepsy characterised by the occurrence of partial-onset seizure with or without secondary generalisation. In this type of epilepsy, fits first affect only one side of your brain. However, these may then spread to larger areas on both sides of your brain; ▪ in association with other antiepileptic medicines in adults, adolescents and children aged 4 years and older to treat primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in patients with idiopathic generalised epilepsy (the type of epilepsy that is thought to h Przeczytaj cały dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Vimpat 50 mg film-coated tablets Vimpat 100 mg film-coated tablets Vimpat 150 mg film-coated tablets Vimpat 200 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Vimpat 50 mg film-coated tablets Each film-coated tablet contains 50 mg lacosamide. Vimpat 100 mg film-coated tablets Each film-coated tablet contains 100 mg lacosamide. Vimpat 150 mg film-coated tablets Each film-coated tablet contains 150 mg lacosamide. Vimpat 200 mg film-coated tablets Each film-coated tablet contains 200 mg lacosamide. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet Vimpat 50 mg film-coated tablets Pinkish, oval film-coated tablets with approximate dimensions of 10.4 mm x 4.9 mm, and debossed with ‘SP’ on one side and ‘50’ on the other side. Vimpat 100 mg film-coated tablets Dark yellow, oval film-coated tablets with approximate dimensions of 13.2 mm x 6.1 mm, and debossed with ‘SP’ on one side and ‘100’ on the other side. Vimpat 150 mg film-coated tablets Salmon, oval film-coated tablets with approximate dimensions of 15.1 mm x 7.0 mm, and debossed with ‘SP’ on one side and ‘150’ on the other side. Vimpat 200 mg film-coated tablets Blue, oval film-coated tablets with approximate dimensions of 16.6 mm x 7.8 mm, and debossed with ‘SP’ on one side and ‘200’ on the other side. 3 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Vimpat is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. Vimpat is indicated as adjunctive therapy • in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. • in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilep Przeczytaj cały dokument